UNSPSC 51421604: Halobetasol or ulobetasol

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H27ClF2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9P6159HM7T, chemically known as 21-chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate but generally known as halobetasol, which bears US NIH Compound Identifier 48175. European Medicines Agency schedules Halobetasol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11379MIG.

World Health Organization schedules halobetasol in its Anatomical Therapeutic Chemical (ATC) Classification. Halobetasol or ulobetasol bears US NLM identifiers UMLS ID C0082787 and NCI Concept Code C61781. SMILES: CLCC(=O)C1(OC(=O)CC)C2(C(C3C(F)(C(O)C2)C2(C(=CC(=O)C=C2)C(F)C3)C)CC1C)C.

UNSPSC 51421604 Halobetasol or ulobetasol is a Commodity code with virtually no recent activity directly aligned to its stated scope. The two posted opportunities in the source—a Seminole County naloxone procurement and a Texas HHS pharmacy benefit management RFI—fall outside the category of corticosteroid pharmaceutical products that the code nominally covers. Naloxone is an opioid antagonist unrelated to halobetasol or other corticosteroids; the Texas RFI addresses prescription fulfillment infrastructure and direct-to-manufacturer relationships rather than specific drug products. No recent state or local solicitations in the source material show procurement of halobetasol, ulobetasol, or related potent topical corticosteroids for state health departments, Medicaid agencies, correctional systems, or other typical state and local end-users of pharmaceutical products.

The mismatch between the code's pharmaceutical product scope and the opportunities tagged to it signals either a tagging error in the underlying procurement database or a dramatic shift in how state and local governments are categorizing pharmaceutical purchases. Until the source supports opportunities aligned to the actual halobetasol or ulobetasol product line—such as state Medicaid formulary purchases, correctional health procurements, or public health agency pharmaceutical contracts—this code shows no actionable recent activity for vendors in corticosteroid supply.